Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine
| Autor: | Jennifer S. Read, Adriana Weinberg, William A. Meyer, Myron J. Levin, Alfred J. Saah, Anna-Barbara Moscicki, Sharon Huang, Kelly Richardson, Lin-Ye Song |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine Time Factors 030106 microbiology Immunization Secondary HIV Infections Antibodies Viral Placebo Article Persistence (computer science) Placebos 03 medical and health sciences 0302 clinical medicine Immune system Human Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18 Immunity Humans Medicine 030212 general & internal medicine Child Immunoassay General Veterinary General Immunology and Microbiology biology medicine.diagnostic_test business.industry Papillomavirus Infections Public Health Environmental and Occupational Health Antibody titer Vaccination Infectious Diseases Immunology biology.protein Molecular Medicine Female Antibody business Follow-Up Studies |
| Zdroj: | Vaccine. 35:1712-1720 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2017.02.021 |
| Popis: | Objective Although HIV-infected children are recommended to receive quadrivalent human papillomavirus vaccine (QHPV) there is limited information on their response to QHPV. This study in HIV-infected children, evaluated the magnitude and duration of immune responses to QHPV. This report describes type-specific serum antibody responses over a 4-to-5 year period after either 3 or 4 doses of QHPV. Design/methods HIV-infected children, ages 7-to-11 years, received 3 doses of QHPV (n = 96) or placebo (n = 30). At 72 weeks QHPV recipients received a fourth dose (n = 84), while placebo recipients began the 3-dose QHPV schedule (n = 27). HPV serotype-specific antibody was determined, by competitive Luminex immunoassay (cLIA) and IgG Luminex immunoassay, at 2, 3.5, and 4-to-5 years after the last dose of QHPV in each treatment arm. Results At 4-to-5 years after the last dose of QHPV, antibody titers were significantly higher in 4-dose than in 3-dose group. However, the proportion of vaccinees with a seroresponse in the cLIA assay was not different between the two groups (86–93% for HPV types 6, 11, and 16, and 64% for HPV type 18). These results were very similar to the seroresponse rate in these HIV-infected children at 1 month after completing vaccination. Conclusions Children with well-controlled HIV infection who receive 3 doses of the QHPV vaccine maintain seropositivity and antibody levels that are generally similar to children of the same age who are not HIV-infected. Antibody titer correlated strongly with low log HIV RNA, low CD8%, and high CD4%. Additionally, a fourth dose of vaccine in HIV-infected children produces a marked rise in antibody characteristic of an anamnestic response and persistence of high antibody levels. Study identification: IMPAACT P1085 (V501-021). CLINICALTRIALS.GOV identifier: NCT01206556 . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect